Composition containing a DPP-IV inhibitor for preventing or treating renal diseases

Patent metadata

Field	Value
Publication number	US-10159667-B2
Application number	US-201414392160-A
Country	US
Kind code	B2
Filing date	Jun 17, 2014
Priority date	Jun 26, 2013
Publication date	Dec 25, 2018
Grant date	Dec 25, 2018

Abstract

The present invention relates to a composition for preventing or treating renal diseases. The composition of the present invention improves lipid metabolism, prevents histological damage including renal fibrosis, alleviates microalbuminuria, and maintains nephrons of renal glomeruli. Therefore, the composition is useful for treating renal diseases.

First claim

The invention claimed is:

1. A method of treating a renal disease in a subject who does not have diabetes, comprising:
administering to the subject who has the renal disease who does not have diabetes a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula 1:

or a pharmaceutically acceptable salt thereof, wherein:
X is OR 1 and R 1 is tert-butyl; and
the renal disease is a glomerulonephritis.

2. The method of claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid and adipic acid.

3. The method of claim 1 , wherein the pharmaceutical composition further comprises an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, wherein:
the angiotensin converting enzyme inhibitor is selected from the group consisting of captopril, enalapril, benazepril, imidapril, lisinopril, prinopril, ramipril, moexipril, fosinopril and quinapril; and
the angiotensin II receptor blocker is selected from the group consisting of candesartan, eprosartan, irbesartan, losartan, telmisartan and valsartan.

Assignees

• Dong A St Co Ltd
• Univ Korea Res & Bus Found

Inventors

• Cha Dae Ryong
• Kang Young Sun
• Cha Jin Joo
• Lee Ji Eun
• Kim Hyun Wook
• Lee Mi Hwa
• Kim Jung Eun
• Kim Mi-Kyung
• Son Moon-Ho
• Kim Soon Hoe

Classifications

• A61K31/495 Primary

  having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61P13/12

  of the kidneys · CPC title

• A61K31/4965 Primary

  Non-condensed pyrazines · CPC title